# US 2025/0375534 A1 · Complexes for delivery of nucleic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375534 A1
- Document ID: US20250375534A1
- Status: Published application
- Kind: A1
- Application number: 18/869,559
- Filed: 2023-05-29
- Published: 2025-12-11
- Earliest claimed: 2022-05-30
- Assignees: BioNTech SE
- Applicants: BioNTech SE
- Inventors: Jorge Moreno Herrero; Irena Vlatkovic; Heinrich Haas; Stephanie Erbar; Egon Jack Jacobus Ambuludi; Louisa Zimmermann; Katalin Karikó; Jason Matthew Keller; Maximiliano Luis Cacicedo; Hossam Hefesha
- Web page: https://patentgrep.com/patent/US20250375534A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/0041: {the non-active part being polymeric}
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or a cationic polymer, wherein nucleic acid particles described herein reduce inflammatory response and/or increase protein or antigen expression associated with previous formulations.

## Claims

### Claim 1

A nucleic acid particle comprising RNA, an immunomodulator, and a cationic lipid or a cationic polymer.

### Claim 2 (depends on 1)

The nucleic acid particle of claim 1, wherein the immunomodulator is not dexamethasone or a dexamethasone prodrug.

### Claim 3 (depends on 1, 2)

The nucleic acid particle of claim 1 or 2, wherein the immunomodulator is about 0.001 to about 50 mol % of the total amount of lipids or polymers and immunomodulators in the nucleic acid particle.

### Claim 4 (depends on 1, 2, 3)

The nucleic acid particle of any one of claims 1-3, wherein the immunomodulator is about 0.01 to about 0.9 mol % of the total amount of lipids or polymers and immunomodulators in the nucleic acid particle.

### Claim 5 (depends on 1, 2, 3, 4)

The nucleic acid particle of any one of claims 1-4, wherein the immunomodulator is a small molecule agonist or antagonist of TLR or PRR receptors.

### Claim 6 (depends on 1, 2, 3, 4)

The nucleic acid particle of any one of claims 1-4, wherein the immunomodulator is a small molecule downstream inhibitor of NF-κβ.

### Claim 7 (depends on 1, 2, 3, 4)

The nucleic acid particle of any one of claims 1-4, wherein the immunomodulator is an sp2-iminosugar glycolipid.

### Claim 8 (depends on 1, 2, 3, 4)

The nucleic acid particle of any one of claim 1-4, wherein the immunomodulator is a TLR inhibitor.

### Claim 9 (depends on 8)

The nucleic acid particle of claim 8, wherein the TLR inhibitor is an inhibitor of TLR2, TLR4, and/or TLR6.

### Claim 10 (depends on 9)

The nucleic acid particle of claim 9, wherein the TLR inhibitor is an inhibitor of TLR4.

### Claim 11 (depends on 10)

The nucleic acid particle of claim 10, wherein the inhibitor of TLR4 is TAK-242.

### Claim 12 (depends on 1, 2, 3, 4)

The nucleic acid particle of any one of claims 1-4, wherein the immunomodulator is a terpenoid.

### Claim 13 (depends on 12)

The nucleic acid particle of claim 12, wherein the terpenoid is a triterpene.

### Claim 14 (depends on 13)

The nucleic acid particle of claim 13, wherein the triterpene is synthetic or natural derivative of amyrin, betulinic acid, oleanolic acid, sterols, squalene or ursolic acid.

### Claim 15 (depends on 14)

The nucleic acid particle of claim 14, wherein the immunomodulator is a sterol.

### Claim 16 (depends on 15)

The nucleic acid particle of claim 15, wherein the sterol is a cortiocosteroid.

### Claim 17 (depends on 16)

The nucleic acid particle of claim 16, wherein the corticosteroid is a glucocorticoid.

### Claim 18 (depends on 17)

The nucleic acid particle of claim 17, wherein the glucocorticoid is prednisolone, fluticasone propionate, budesonide or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2, 3, 4)

The nucleic acid particle of any one of claims 1-4, wherein the immunomodulator is an inflammasome inhibitor.

### Claim 20 (depends on 19)

The nucleic acid particle of claim 19, wherein the inflammasome inhibitor is a NLRP3 inflammasome inhibitor, an AIM2 inflammasome inhibitor, a caspase-1 inhibitor, or a pan-casase inhibitor.

### Claim 21 (depends on 20)

The nucleic acid particle of claim 20, wherein the inflammasome inhibitor is selected from glyburide (e.g., glibenclamide), 5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)-ethyl]-benzamide (e.g., 16673-34-0), JC124, FC11A-2, parthenolide, VX-740, VX-765, BAY 11-7082, BHB, MCC950, MNS, CY-09, Tranilast, OLT1177, and oridonin.

### Claim 22 (depends on 20, 21)

The nucleic acid particle of claim 20 or 21, wherein the inflammasome inhibitor is MCC950 or BAY 11-7082.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The nucleic acid particle of any one of claims 1-22, wherein the lipid nanoparticle further comprises one or more additional immunomodulators.

### Claim 24 (depends on 23)

The nucleic acid particle of claim 23, where the one or more additional immunomodulators are or comprise a small molecule agonist or antagonist of TLR or PRR receptors.

### Claim 25 (depends on 23)

The nucleic acid particle of claim 23, where the one or more additional immunomodulators are or comprise an inflammasome inhibitor.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The nucleic acid particle of any one of claims 1-25, wherein the nucleic acid particle comprises the immunomodulator, a cationic lipid, and RNA.

### Claim 27 (depends on 26)

The nucleic acid particle of claim 26, wherein the nucleic acid particle is in the form of a lipid nanoparticle.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The nucleic acid particle of any one of claims 1-27, wherein the cationic lipid is a lipid comprising one or more nitrogen atoms that are cationic or ionizable at physiological pH (e.g., about 7.4).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The nucleic acid particle of any one of claims 1-28, wherein the cationic lipid is selected from Table 1 and/or Table 2.

### Claim 30 (depends on 29)

The nucleic acid particle of claim 29, wherein the cationic lipid is ALC-0315, SM-102, ALC366, DODMA, or HY-501.

### Claim 31 (depends on 27, 28, 29, 30)

The nucleic acid particle of any one of claims 27-30, wherein the cationic lipid is about 30 to about 50 mol % of the total amount of lipids and immunomodulators in the lipid nanoparticle.

### Claim 32 (depends on 27, 28, 29, 30, 31)

The nucleic acid particle of any one of claims 27-31, further comprising a helper lipid.

### Claim 33 (depends on 32)

The nucleic acid particle of claim 32, wherein the helper lipid is a phospholipid.

### Claim 34 (depends on 33)

The nucleic acid particle of claim 33, wherein the helper lipid is selected from: phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidic acids, phosphatidylserines and sphingomyelins, more preferably selected from the group consisting of distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C1-6 Lyso PC), dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), dilauroyl-phosphatidylethanolamine (DLPE), diphytanoyl-phosphatidylethanolamine (DPyPE), and combinations thereof.

### Claim 35 (depends on 34)

The nucleic acid particle of claim 34, wherein the helper lipid is DSPC.

### Claim 36 (depends on 32, 33, 34)

The nucleic acid particle of any one of claims 32-34, wherein the lipid nanoparticle comprises about 5 to about 15 mol % of the helper lipid relative to the total amount of lipids and immunomodulators.

### Claim 37 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The nucleic acid particle of any one of claims 27-36, further comprising a polymer-conjugated lipid.

### Claim 38 (depends on 37)

The nucleic acid particle of claim 37, wherein the polymer-conjugated lipid is a PEG-lipid selected from PEG-DAG, PEG-PE, PEG-S-DAG, PEG2000-DMG, PEG-cer, a PEG dialkyoxypropylcarbamate, ALC-0159, and combinations thereof.

### Claim 39 (depends on 38)

The nucleic acid particle of claim 38, wherein the PEG-lipid is ALC-0159 or PEG2000-DMG.

### Claim 40 (depends on 39)

The nucleic acid particle of claim 39, wherein the PEG-lipid is ALC-0159.

### Claim 41 (depends on 39)

The nucleic acid particle of claim 39, wherein the PEG-lipid is PEG2000-DMG.

### Claim 42 (depends on 38, 39, 40, 41)

The nucleic acid particle of any one of claims 38-41, wherein the lipid nanoparticle comprises about 1 to about 5 mol % of the PEG-lipid relative to the total amount of lipids and immunomodulators.

### Claim 43 (depends on 27)

The nucleic acid particle of claim 27, wherein the cationic lipid is ALC-0315, and the lipid nanoparticle further comprises a helper lipid that is DSPC, and a PEG-lipid that is ALC-0159.

### Claim 44 (depends on 27)

The nucleic acid particle of claim 27, wherein the cationic lipid is SM-102, and the lipid nanoparticle further comprises a helper lipid that is DSPC, and a PEG-lipid that is PEG2000-DMG.

### Claim 45 (depends on 27)

The nucleic acid particle of claim 27, wherein the cationic lipid is HY-501, and the lipid nanoparticle further comprises a helper lipid that is DSPC.

### Claim 46 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The nucleic acid particle of any one of claims 27-45 further comprising an additional terpenoid.

### Claim 47 (depends on 46)

The nucleic acid particle of claim 46, wherein the additional terpenoid is a triterpene.

### Claim 48 (depends on 47)

The nucleic acid particle of claim 47, wherein the triterpene is a sterol.

### Claim 49 (depends on 48)

The nucleic acid particle of claim 48, wherein the sterol is selected from p-sitosterol, stigmasterol, cholesterol, cholecalciferol, ergocalciferol, calcipotriol, botulin, lupeol, ursolic acid, oleanolic acid, cycloartenol, lanosterol, or α-tocopherol.

### Claim 50 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The nucleic acid particle of any one of claims 27-49, wherein the lipid nanoparticle further comprises a surfactant that is or comprises a polysorbate, a poloxamer, and/or a compound comprising an amphiphilic moiety selected from polyalkylene glycols (e.g., polyethylene glycol), poly(2-oxazoline), poly(2-oxazine), polysarcosine, polyvinylpyrrolidone, and poly[N-(2-hydroxypropyl)methacrylamide, wherein the amphiphilic moiety is bonded to one or more C1-2-C20 aliphatic groups.

### Claim 51 (depends on 50)

The nucleic acid particle of claim 50, wherein the surfactant is or comprises a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof.

### Claim 52 (depends on 27)

The nucleic acid particle of claim 27, wherein the lipid nanoparticle comprises:
i) about 30 to about 50 mol % of the cationic lipid;
ii) about 1 to about 5 mol % of a PEG-lipid; and
iii) about 5 to about 15 mol % of a helper lipid.

### Claim 53 (depends on 52)

The nucleic acid particle of claim 52, wherein the lipid nanoparticle comprises:
i) about 30 to about 50 mol % of ALC-0315;
ii) about 1 to about 5% mol % of ALC-0159; and
iii) about 5 to about 15% mol % of DSPC.

### Claim 54 (depends on 53)

The nucleic acid particle of claim 53, wherein the lipid nanoparticle comprises:
i) about 47.5 mol % of ALC-0315;
ii) about 1.8 mol % of ALC-0159; and
iii) about 10 mol % of DSPC.

### Claim 55 (depends on 27)

The nucleic acid particle of claim 27, wherein the lipid nanoparticle comprises:
i) about 30 to about 50 mol % of SM-102;
ii) about 1 to about 5 mol % of a PEG2000-DMG; and
iii) about 5 to about 15 mol % of DSPC.

### Claim 56 (depends on 55)

The nucleic acid particle of claim 55, wherein the lipid nanoparticle comprises:
i) about 50 mol % of SM-102;
ii) about 1.5 mol % of PEG2000-DMG; and
iii) about 10 mol % of DSPC.

### Claim 57 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The nucleic acid particle of any one of claims 27-56, wherein the lipid nanoparticle is characterized by an N/P ratio that is from about 4:1 to about 12:1.

### Claim 58 (depends on 57)

The nucleic acid particle of claim 57, wherein the lipid nanoparticle is characterized by an N/P ratio that is about 6:1.

### Claim 59 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The nucleic acid particle of any one of claims 27-58, wherein the lipid nanoparticle has a diameter of about 50 nm to about 150 nm.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The nucleic acid particle of claims 1-25, wherein the nucleic acid particle comprises the immunomodulator, the cationic polymer, and RNA.

### Claim 61 (depends on 60)

The nucleic acid particle of claim 60, wherein the cationic polymer is poly(ethyleneimine) or poly(propyleneimine).

### Claim 62 (depends on 60, 61)

The nucleic acid particle of claim 60 or 61, wherein the nucleic acid particle further comprises a secondary polymer.

### Claim 63 (depends on 62)

The nucleic acid particle of claim 62, wherein the secondary polymer is polysarcosine.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The nucleic acid particle of any one of claims 1-63, wherein the RNA is mRNA

### Claim 65 (depends on 64)

The nucleic acid particle of claim 64, wherein the RNA is modRNA, circRNA, saRNA, taRNA, or uRNA.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A method of increasing or causing increased expression of RNA in a target in a subject, the method comprising administering to the subject the nucleic acid particle of any one of claims 1-65.

### Claim 67 (depends on 66)

The method of claim 66, wherein the target is selected from the lungs, liver, spleen, heart, brain, lymph nodes, bladder, kidneys, and pancreas.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A method of treating a disease, disorder, or condition in a subject comprising administering to the subject the nucleic acid particle of any one of claims 1-65.

### Claim 69 (depends on 68)

The method of claim 68, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

### Claim 70 (depends on 66, 67, 68, 69)

The method of any one of claims 66-69, wherein the nucleic acid particle is administered parenterally or intranasally.

### Claim 71 (depends on 70)

The method of claim 70, wherein the nucleic acid particle is administered intramuscularly, subcutaneously, intradermally, or intravenously.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A nucleic acid particle of any one of claims 1-65 for use as a medicament.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

A nucleic acid particle of any one of claims 1-65 for use in the treatment and/or prevention of a disease or disorder, wherein the disease or disorder is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.
